Click on the subcategory below to find drug monographs for that particular area.
Early progress has been made in developing a treatment that might one day help the immune system defend itself against cancer.
The FDA has approved a new indication for Arzerra (ofatumumab; GlaxoSmithKline) to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).
AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Six percent of patients with colorectal cancer (CRC) have interval cancers, which develop within six to 60 months of colonoscopy.
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
Red flag - Unintentional weight loss
Clinical Review - Acute myeloid leukaemia
Clinical Review: Diffuse large B-cell lymphoma